Allied Healthcare Group: Dr Julian Chick to fill the chief operating officer’s seat

Allied Healthcare Group (ASX: AHZ) has welcomed Dr Julian Chick to the executive team as chief operating officer to help drive the commercialisation of the company’s product pipeline and develop further commercial opportunities for the group.

Chick has spent the last 10 years in the biotechnology sector, most recently building up a successful contract research and corporate advisory business at JDJ Bioservices, and prior to that was an executive at Avexa and Amrad.

He is also a non-executive director of the industry body BioMelbourne Network.

Chick, who is scheduled to begin his new role in the New Year, will retain his position as non-executive director of Coridon – the DNA vaccine development company led by Professor Ian Frazer, and part of the Allied Group.

Managing director Lee Rodne said, “We are very excited to have the experience and industry knowledge that Dr Chick will bring to our executive team.”

“He joins us at an important time and will play a key role in developing further commercial opportunities for the Allied Group.”

Chick will focus on the operational side of the business as well as exploring M&A and business development opportunities that will help build the Allied business.

Allied has begun discussions on partnering and commercial distribution opportunities for subsidiary Celxcel’s lead product CardioCel.

The company has also had recent success in a tissue heart valve study of its ADAPT® Tissue Engineering technology which has demonstrated a reduction in visible calcification of implanted tissue heart valves.

The ADAPT® Tissue Engineering technology could extend the lifespan of implanted tissue beyond its current 10 years.

Originally published at: http://www.proactiveinvestors.com.au/companies/news/23177/allied-healthcare-group-dr-julian-chick-to-fill-the-chief-operating-officers-seat-23177.html